Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 37 | ECE2015 | Next issue

17th European Congress of Endocrinology

Guided Posters

Pituitary–Therapy of Cushing's disease

ea0037gp.22.01 | Pituitary–Therapy of Cushing's disease | ECE2015

Phase III, multicentre, double-blind, randomised withdrawal study of osilodrostat (LCI699) in patients with Cushing's disease: a study design

Shimatsu Akira , Sauter Nicholas , Kelly Roxzana , Unge Peter , Zhi Xin , Fleseriu Maria

Introduction: Osilodrostat is a potent, oral inhibitor of 11β-hydroxylase, the enzyme that catalyses final step of cortisol biosynthesis. In a phase II study, 15/19 patients treated with osilodrostat met the primary endpoint (normal urinary free cortisol (UFC) at 22 weeks); osilodrostat was generally well tolerated. This phase III study aims to confirm the efficacy and long-term safety of osilodrostat.Patients and methods: Adults (18–75 years) ...

ea0037gp.22.02 | Pituitary–Therapy of Cushing's disease | ECE2015

Surgical outcome and factors associated with Cushing's disease recurrence in 101 consecutive patients operated on by a single pituitary neurosurgeon: the Cleveland Clinic experience

Johnston Philip C , Hamrahian Amir H , Bena Jim , Weil Bob , Kennedy Laurence

Background: Transsphenoidal tumour resection (TSS) is the first-line treatment for Cushing’s disease (CD). With an experienced neurosurgeon, immediate remission rates >80% are expected for patients with microadenomas (<10 mm).Aim: To report initial and long-term remission rates in a specialist centre, and to ascertain factors associated with disease recurrence after TSS.Methods: Patients with CD (n=101, 28M, 7...

ea0037gp.22.03 | Pituitary–Therapy of Cushing's disease | ECE2015

Impact of preoperative magnetic resonance in surgical care of patients with Cushing's disease

Guelho Daniela , Martins Diana , Paiva Isabel , Cardoso Luis , Vicente Nuno , Oliveira Diana , Balsa Margarida , Carrilho Francisco

Introduction: Cushing’s disease (CD) is a rare disorder caused by an ACTH-secreting pituitary adenoma. Transsphenoidal surgery (TSS) is the recommended first-line treatment. However, an equivocal or even normal preoperative MRI can preclude the surgical management and the outcome of these patients.Objectives: Evaluate the relationship between preoperative MRI and TSS efficacy in patients with CD.Methods: Retrospective cohort s...

ea0037gp.22.04 | Pituitary–Therapy of Cushing's disease | ECE2015

Long-term (5 years) treatment of Cushing's disease with pasireotide

Petersenn Stephan , Salgado Luiz R , Schopohl Jochen , Portocarrero-Ortiz Lesly , Arnaldi Giorgio , Lacroix Andre , Ravichandran Shoba , Kandra Albert , Bagulho Teresa , Biller Beverly MK

Background: In a large 12-month Phase III study, pasireotide led to rapid and sustained decreases in UFC and provided clinical benefit in patients with Cushing’s disease. Here, we report data following an open-label, open-ended extension.Methods: 162 patients with persistent/recurrent or de novo Cushing’s disease were randomized in the core study. 58 patients with mean UFC≤ULN or clinical benefit at month 12 entered the extension...

ea0037gp.22.05 | Pituitary–Therapy of Cushing's disease | ECE2015

Effects of osilodrostat (LCI699) on cytochrome P450 enzymes in healthy volunteers indicates a low drug–drug interaction potential

Ting Lillian , Tripathi Anadya Prakash , Darstein Christelle , White Tracy , Sauter Nicholas

Introduction: In vitro assessments of osilodrostat (LCI699), a potent oral inhibitor of 11β-hydroxylase suggested potential drug–drug interactions (DDIs) with cytochrome P450 (CYP) enzyme metabolism. This clinical study evaluated the effect of osilodrostat on the pharmacokinetics (PK) of CYP1A2, CYP2C19, CYP2D6, and CYP3A4 probe substrates, caffeine, omeprazole, dextromethorphan, and midazolam, respectively.Methods: A single-centre, op...

ea0037gp.22.06 | Pituitary–Therapy of Cushing's disease | ECE2015

A specific nursing educational programme in patients with Cushing's syndrome

Martinez-Momblan M Antonia , Porta Nuria , Gomez Carmen , Esteve Julia , Santos Alicia , Ubeda Inmaculada , Halperin Irene , Campillo Beatriz , Guillaumet Montserrat , Webb Susan M , Resmini Eugenia

Context: Cushing’s syndrome (CS) is a rare endocrine disease, due to cortisol hypersecretion. CS patients have several comorbidities, often still present after biochemical cure. There are no specific nursing healthcare programs to address this disease and achieve improved health related quality of life (HRQoL). Thus, an educational nursing intervention in these patients, through the development and promotion of specific educational tools, appears to be justified.<p cl...

ea0037gp.22.07 | Pituitary–Therapy of Cushing's disease | ECE2015

Neurosurgery outcome in patients with Cushing's disease with and without visualised pituitary adenoma on MRI, who underwent inferior petrosal sinus sampling

Belaya Zhanna , Khandaeva Patimat , Rozhinskaya Ludimila , Vorontsov Aleksandr , Sitkin Ivan , Grigoriev Andrey , Ivashenko Oksana , Dzeranova Larisa , Melnichenko Galina

Objective: To estimate the outcome of neurosurgery in patients with Cushing’s disease (CD) with and without pituitary adenoma visualisation on MRI.Material and methods: Patients with confirmed CD (11.2008–11.2014) by both inferior petrosal sinus sampling (IPSS) and histological evaluation after neurosurgery were enrolled into the study. Subjects were referred for IPSS because of non-visualised pituitary adenoma or contradictory results of non-i...